AIM
Levetiracetam is a widely used anti-epileptic in the critical care
setting that is almost exclusively (>90%) renally
excreted. A significant number of critically unwell patients develop
renal failure requiring haemofiltration. This paper investigates the
pharmacokinetics of levetiracetam in such patients and the implications
on dosing strategies.